INS and diabetic kidney disease: In contrast, glycaemic optimisation using sensor-augmented insulin pump therapy and continuous glucose monitoring (CGM) systems reduced glycaemic variability and improved time in range, which was associated with a reduction in albuminuria in people with type 1 diabetes and DKD [15].